Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000891681 | SCV001035508 | likely benign | Holocarboxylase synthetase deficiency | 2024-01-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004028409 | SCV004882387 | uncertain significance | Inborn genetic diseases | 2022-04-29 | criteria provided, single submitter | clinical testing | The c.21G>A (p.M7I) alteration is located in exon 4 (coding exon 1) of the HLCS gene. This alteration results from a G to A substitution at nucleotide position 21, causing the methionine (M) at amino acid position 7 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000891681 | SCV002083751 | likely benign | Holocarboxylase synthetase deficiency | 2021-05-25 | no assertion criteria provided | clinical testing |